Fujian Medical University Union Hospital, Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Cancer Center, Fuzhou, Fujian, People's Republic of China.
Medicine (Baltimore). 2021 Jan 22;100(3):e24365. doi: 10.1097/MD.0000000000024365.
Percutaneous ethanol injection is a well-known ablation therapy for hepatocellular carcinoma and is well-tolerated, inexpensive, and effective with few adverse events. In this study, another type of ethanol injection was introduced in the present study.Sixty two patients with hepatocellular carcinoma received 133 percutaneous peritumor ethanol injection treatments and the 15-year follow-up outcomes were analyzed through a collected database.The technical efficiency was 89.5% (119/133 treatments) after the first percutaneous peritumor ethanol injection procedure. However, after the second repeated percutaneous peritumor ethanol injection procedure, technical efficiency increased to 98.5% (131/133 treatments). The 1 year, 3 years, 5 years, 10 years, and 15 years rates of tumor recurrence were 12.9%, 50.0%, 59.7%, 74.2%, and 74.2%, respectively. Multivariate analysis demonstrated that diabetes, Child-Pugh class B, and tumor size greater than 2 cm were significantly related to tumor recurrence. The 1 year, 3 years, 5 years, 10 years, and 15 years rates of overall survival were 98.4%, 83.6%, 61.3%, 19.4%, and 0%, respectively. Multivariate analysis demonstrated that Child-Pugh class B, tumor size greater than 2 cm, and multiple tumors were significantly related to overall survival.Compared with other ablation methods (including peritumor ethanol injection), percutaneous peritumor ethanol injection can avoid tumor ruptures, reduce tumor proliferation and metastasis, and is suitable for the treatment of small tumors. In addition, when combined with other treatment methods, percutaneous peritumor ethanol injection can form a tumor metastatic isolation zone in advance and improve the comprehensive treatment effect.
经皮乙醇注射是一种广为人知的肝癌消融治疗方法,具有耐受性好、价格低廉、疗效确切、不良反应少等优点。在本研究中,引入了另一种类型的乙醇注射。62 例肝癌患者接受了 133 次经皮肿瘤周围乙醇注射治疗,并通过收集的数据库分析了 15 年的随访结果。首次经皮肿瘤周围乙醇注射后,技术有效率为 89.5%(119/133 次治疗)。然而,在第二次重复经皮肿瘤周围乙醇注射后,技术有效率提高至 98.5%(131/133 次治疗)。1 年、3 年、5 年、10 年和 15 年的肿瘤复发率分别为 12.9%、50.0%、59.7%、74.2%和 74.2%。多因素分析表明,糖尿病、Child-Pugh 分级 B 和肿瘤直径大于 2cm 与肿瘤复发显著相关。1 年、3 年、5 年、10 年和 15 年的总生存率分别为 98.4%、83.6%、61.3%、19.4%和 0%。多因素分析表明,Child-Pugh 分级 B、肿瘤直径大于 2cm 和多发肿瘤与总生存率显著相关。与其他消融方法(包括肿瘤周围乙醇注射)相比,经皮肿瘤周围乙醇注射可以避免肿瘤破裂,减少肿瘤增殖和转移,适用于治疗小肿瘤。此外,当与其他治疗方法联合使用时,经皮肿瘤周围乙醇注射可以提前形成肿瘤转移隔离区,提高综合治疗效果。